Building Patent Matrix

BellaGen has broken the monopoly of core technology for foreign gene editing and is the first company in China to succeed in independently developing the underlying patented technology for gene editing. We have independently developed the “gene scissors” family represented by CRISPR Cas SF01 and CRISPR Cas SF02, and achieved a series of breakthroughs in both common and key technology. Up to now, we have applied for more than 160 patents, including 29 PCT patent applications, and have been granted more than 40 patents (Note: patent data as of December 2022).